Implantable medical devices for treating or preventing restenosis

• US 20050159809A1
• Filed: 12/10/2004
• Published: 07/21/2005
• Est. Priority Date: 01/21/2004
• Status: Abandoned Application

• Current Assignee: Medtronic Vascular, Inc. (Medtronic Plc)
• Original Assignee: Medtronic Vascular, Inc. (Medtronic Plc)
• Inventors: Hezi-Yamit, Ayala, Singh, Sabeena
• Application Number:
  US11/009,863
• Publication Number:
  US 20050159809A1
• Time in Patent Office: Days
• US Class Current: 623/1.420
• CPC Class Codes: A61F 2/90 characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2210/0076 multilayered, e.g. laminated structures
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

Implantable medical devices having anti-restenotic antioxidants are disclosed. The anti-restenotic medical devices include stents and vascular grafts. Intravascular stents are preferred medical devices. The preferred anti-restenotic antioxidant is probucol. The medical devices can have coatings that include a polymer matrix. Related methods of treating or inhibiting restenosis using the Implantable medical devices are also disclosed.

Claims

1. An implantable medical device comprising:

a coating having at least one anti-restenotic antioxidant.

2. The implantable medical device according to claim 1 further comprising a biocompatible polymer matrix.

3. The implantable medical device according to claim 1 or claim 2 wherein said medical device is selected from the group consisting of vascular stents, urethral stents, biliary stents and endovascular grafts.

4. The implantable medical device according to claim 3 wherein said anti-restenotic antioxidant is lipid soluble.

5. The implantable medical device according to claim 4 wherein said lipid soluble anti-restenotic antioxidant is {[bis(3,5-di-tert-butyl-4-hydroxyphenyl)thio]propane} (probucol).

6. The implantable medical device according to claim 4 or 5 wherein said polymer matrix comprises at least one biocompatible polymer selected from the group consisting of polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers, ethylene-co-vinylacetate, polybutylmethacrylate, vinyl halide polymers and copolymers, such as polyvinyl chloride;

polyvinyl ethers, such as polyvinyl methyl ether;

polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride;

polyacrylonitrile, polyvinyl ketones;

polyvinyl aromatics, polyvinyl esters, copolymers of vinyl monomers, ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, ethylene-vinyl acetate copolymers;

polyamides, alkyd resins;

polycarbonates, polyoxymethylenes, polyimides, polyethers, epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, carboxymethyl cellulose, phosphatidylcholine, fibrin and combinations thereof.

7. A method for treating or inhibiting restenosis comprising:

administering an anti-restenotic antioxidant to a specific site in a mammalian vessel at subject to restenosis such that restenosis is treated or inhibited.

8. The method according to claim 7 wherein said specific site in said mammalian vessel subject to restenosis is the vessel lumen or adventitia.

9. The method according to claim 7 or 8 wherein said administered anti-restenotic antioxidant is probucol.

10. The method according to claim 7 wherein said anti-restenotic antioxidant is administered by means of an implantable medical device having a coating comprising said anti-restenotic antioxidant and a polymer matrix.